Loading…
PharmaCyte Biotech, Inc. is projected to rise to $0.9388 by 2027, a +35% move from its current price of $0.6965. PMCB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $0.6718 | $0.6961 | $0.7213 | -0.06% |
| Jul 15 | $0.6615 | $0.6957 | $0.7316 | -0.12% |
| Jul 16 | $0.6537 | $0.6953 | $0.7395 | -0.18% |
| Jul 17 | $0.6471 | $0.6949 | $0.7461 | -0.24% |
| Jul 18 | $0.6414 | $0.6945 | $0.7519 | -0.29% |
| Jul 19 | $0.6361 | $0.694 | $0.7572 | -0.35% |
| Jul 20 | $0.6313 | $0.6936 | $0.7621 | -0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6313 | $0.6936 | $0.7621 | -0.41% |
| Week 2 | $0.6047 | $0.6908 | $0.7891 | -0.82% |
| Week 3 | $0.5845 | $0.6879 | $0.8097 | -1.23% |
| Week 4 | $0.5676 | $0.6851 | $0.827 | -1.64% |
| Week 5 | $0.5528 | $0.6823 | $0.8421 | -2.04% |
| Week 6 | $0.5396 | $0.6795 | $0.8556 | -2.44% |
| Week 7 | $0.5275 | $0.6767 | $0.868 | -2.84% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
PharmaCyte Biotech, Inc. is a biotechnology company focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.
PharmaCyte Biotech was incorporated in 1996 and is headquartered in Las Vegas, Nevada. It was formerly known as Nuvilex, Inc.\n\nThis description highlights PharmaCyte Biotech’s niche within the healthcare sector and its historical branding. The information provided establishes its identity, location, and the core technology underpinning its therapeutic approach without detailing external partnerships or milestones not listed here.
PharmaCyte Biotech, Inc. trades as PMCB in the Healthcare sector. The current price is $0.711 and the company carries a market capitalization of $7.63M, with a market rank of 5208.
The stock’s near-term outlook is framed by a multi-year forecast that projects upside potential, including a 2050 max price of $8.10 and a 2050 average price of $3.78. These figures imply meaningful, though uncertain, appreciation from the current level.
A major floor 15.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 23.1% above — a clean break opens room to run.
A major ceiling 36.5% above — clearing it would confirm fresh momentum.
Key PMCB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PMCB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7095 | Sell | $0.7088 | Sell |
| MA 10 | $0.7274 | Sell | $0.7223 | Sell |
| MA 20 | $0.75 | Sell | $0.7367 | Sell |
| MA 50 | $0.7601 | Sell | $0.7481 | Sell |
| MA 100 | $0.7344 | Sell | $0.7628 | Sell |
| MA 200 | $0.8094 | Sell | $0.8395 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.47 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -119.84 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -10.28 | Sell |
| Bollinger %B (20,2) | 0.12 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.16 | Sell |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 27.04 | Buy |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 0.69 | Buy |
| ADX (14) | 8.47 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is Bearish, with RSI(14) at 40. The moving averages show SMA50 at $0.7629 and SMA200 at $0.8136. Support is identified at $0.70 and resistance at $0.8573. The 30-day price range stretches from $0.55 to $0.9192, and annualized volatility is high at 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.6507 | $0.6965 | $0.9033 | 0% | Neutral | |
| $0.7264 | $0.9388 | $1.30 | +35% | Bullish | |
| $0.7495 | $1.01 | $1.45 | +44% | Bullish | |
| $0.7217 | $0.9994 | $1.50 | +43% | Bullish | |
| $0.7675 | $1.09 | $1.69 | +57% | Bullish | |
| $0.7133 | $1.04 | $1.65 | +50% | Bullish | |
| $0.6882 | $1.03 | $1.67 | +48% | Bullish | |
| $0.7911 | $1.21 | $2.01 | +74% | Bullish | |
| $0.9575 | $1.50 | $2.53 | +115% | Bullish | |
| $1.04 | $1.65 | $2.84 | +137% | Bullish | |
| $1.13 | $1.98 | $3.66 | +184% | Bullish | |
| $1.73 | $3.62 | $7.44 | +420% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.6507 | $0.6965 | $0.844 | +0.00% |
| August 2026 | $0.5662 | $0.6737 | $0.827 | -3.28% |
| September 2026 | $0.5497 | $0.6601 | $0.8219 | -2.02% |
| October 2026 | $0.5769 | $0.6983 | $0.88 | +5.79% |
| November 2026 | $0.5893 | $0.7182 | $0.9142 | +2.85% |
| December 2026 | $0.5734 | $0.7031 | $0.9033 | -2.10% |
Click any year to see its month-by-month PMCB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PMCB price prediction for 2026 points to an average of $0.6965 (low $0.6507, high $0.9033) — a potential gain of 0% on today's $0.6965. A consolidation phase looks the most probable path here.
In 2027, PMCB is projected to trade between $0.7264 and $1.30, averaging $0.9388 — a potential gain of +35% from today's $0.6965. That is up +35% on the projected 2026 average. Momentum favours further upside here.
PharmaCyte Biotech, Inc.'s 2028 outlook centres on $1.01, within a $0.7495 to $1.45 range. That is up +7% on the projected 2027 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, PMCB could reach as high as $1.50, with a base case around $0.9994 and support toward $0.7217 — roughly +43% from $0.6965. Momentum favours further upside here.
Expect PMCB to range from $0.7675 to $1.69 through 2030. The $1.09 average target implies a +57% move from current prices. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The PMCB price prediction for 2031 points to an average of $1.04 (low $0.7133, high $1.65) — a potential gain of +50% on today's $0.6965. Momentum favours further upside here.
In 2032, PMCB is projected to trade between $0.6882 and $1.67, averaging $1.03 — a potential gain of +48% from today's $0.6965. That is -1% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
PharmaCyte Biotech, Inc.'s 2033 outlook centres on $1.21, within a $0.7911 to $2.01 range. That is up +18% on the projected 2032 average. That marks a +74% change versus current levels. Momentum favours further upside here.
By 2034, PMCB could reach as high as $2.53, with a base case around $1.50 and support toward $0.9575 — roughly +115% from $0.6965. Buyers look set to stay in control over this stretch.
Expect PMCB to range from $1.04 to $2.84 through 2035. The $1.65 average target implies a +137% move from current prices. That is up +10% on the projected 2034 average. Momentum favours further upside here.
The PMCB price prediction for 2040 points to an average of $1.98 (low $1.13, high $3.66) — a potential gain of +184% on today's $0.6965. Buyers look set to stay in control over this stretch.
In 2050, PMCB is projected to trade between $1.73 and $7.44, averaging $3.62 — a potential gain of +420% from today's $0.6965. That is up +83% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in PMCB today (≈ 1,435.750179 PMCB) could be worth
$5,196.26
+$4,196.26 (+420%) by 2050 · US Dollar
Based on the average projected PMCB price of $3.62 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PMCBwould be worth at today's price.
$1,000 invested in PMCB on Jul 10, 2025 (≈ 911.909492 PMCB) would be worth
$635.14
-$364.86 (-36.5%) today · 0.64× · US Dollar
Based on a PMCB entry price of $1.1 vs. today's $0.6965.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.715 | $974.13 | -2.6% |
| 1 month ago | $0.7 | $995 | -0.5% |
| 3 months ago | $0.6531 | $1,066.45 | +6.6% |
| 6 months ago | $0.898 | $775.61 | -22.4% |
| 1 year ago | $1.1 | $635.14 | -36.5% |
| All time (5.0y) ago | $8.28 | $84.14 | -91.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PMCB forecast.
Our base-case forecast reaches $1.40 around 2034.
Implied market cap at $1.40: $15.03M
The multi-year forecast paints a bullish trajectory for PharmaCyte Biotech. In 2026, the min price is $0.6507, the avg is $0.711, the max is $0.9304, with a 0% ROI and Neutral sentiment. From 2027 onward, the model shows bullish sentiment with rising averages: 2027 avg $0.9851 (ROI 38.6%), 2028 avg $1.05 (47.2%), 2029 avg $1.03 (45.3%), 2030 avg $1.15 (61.1%), 2031 avg $1.07 (50.2%), 2032 avg $1.05 (47.4%), 2033 avg $1.27 (78.9%), 2034 avg $1.57 (121.3%), 2035 avg $1.74 (144.1%), 2040 avg $2.06 (190.4%), and 2050 avg $3.78 (431.8%) with a max of $8.10 and bullish sentiment.
These figures illustrate a path of increasing valuation and upside potential, albeit with substantial uncertainty and without guarantees.
Tap a question to reveal the answer.
The forecast shows a 2030 average price of $1.15, with a min of $0.7858 and a max of $1.81, and an estimated ROI of 61.1% with bullish sentiment.
The forecast indicates bullish sentiment from 2027 onward, with 2027 avg $0.9851 and ROI of 38.6%. The path continues higher, with 2030 avg $1.15 and ROI 61.1%, suggesting upside potential but not a guarantee.
Yes—the 2050 forecast includes a max price of $8.10, with a 2050 avg of $3.78 and ROI of 431.8%, indicating substantial potential upside under the high-path scenario.
The current price is $0.711 and the market cap is $7.63M.
The 30-day outlook is Bearish with RSI(14) at 40. SMA50 is $0.7629 and SMA200 is $0.8136. Support is at $0.70 and resistance at $0.8573; the 30-day range is $0.55–$0.9192, and annualized volatility is 70%.
PharmaCyte Biotech, Inc. Community Discussion
0Share your PharmaCyte Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.